

Hepatoprotective properties of the glycolipoprotein extract from *Eisenia foetida*

Akram Jamshidzadeh^{1,2}, Fatemeh Dabagh³, Omid Farshad¹, Mohammad Mehdi Ommati¹, Azadeh Mahdavinia², Negar Azarpira⁴, Maryam Shahbazi², Asma Najibi¹, Reza Heidari^{1,*}

¹Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

²Pharmacology and Toxicology Department, Shiraz University of Medical Sciences, Shiraz, Iran.

³Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

⁴Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

The liver is continuously exposed to a variety of xenobiotics. Several xenobiotics are identified as hepatotoxicants. Hence, finding protective agents for ameliorating xenobiotics-induced liver injury has a great value. *Eisenia foetida*, a kind of “earthworm,” is a source of a wide range of bioactive components. Several investigations have been evaluated the *E. foetida* extract (EFX) for biomedical and nutritional applications. The current study was designed to evaluate the potential hepatoprotective properties of EFX in two experimental models of hepatic damage. Acetaminophen (APAP; 1 g/kg, i.p) was administered as the animal model of acute liver injury in mice. Bile duct ligated (BDL) rats were used as the animal model of chronic hepatic damage. Severe elevation in tissue biomarkers of oxidative stress including lipid peroxidation and hepatic glutathione depletion was evident in both APAP-treated and BDL animals. Moreover, serum biomarkers of liver injury were drastically increased in both acute and chronic animal models of hepatotoxicity. Significant liver tissue histopathological alterations including tissue necrosis, vascular congestion, and inflammatory cells infiltration were detected in APAP-treated and BDL animals. On the other hand, it was found that EFX supplementation (100, 200, 500, and 700 mg/kg, i.p) mitigated oxidative stress markers, decreased serum biomarkers of liver injury, and alleviated liver tissue histopathological changes. The hepatoprotection provided by EFX supplementation in the current study might be mediated through its potential antioxidative mechanisms.

Keywords: Antioxidant, Hepatotoxicity, Liver injury, Natural products, Regenerative medicine.

1. Introduction

Liver is continuously exposed to a wide range of xenobiotics. Exposure to xenobiotics or their reactive metabolites might lead to liver injury (1-3). Therefore, finding hepatoprotective agents has a great value. Recently a great interest has been emerged to find biologically active hepatoprotective agents from natural resources. In this context, a wide range of herbal medicines and their active components have been tested in different experimental models of liver injury (4-10). Amino acids, peptides, proteins, and polyphenol chemicals as well as many other compounds of natural origin are widely evaluated for their protective properties, over and above their potential in regenerating the damaged tissues (11-25).

Earthworms have been used for their great

Corresponding Author: Reza Heidari, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Email: rheidari@sums.ac.ir; rezaheidari@hotmail.com

therapeutic advantages in different regions of the world since ancient times (26, 27). It has been reported that earthworm contains a wide range of bioactive components with different activities (28-32). Interestingly, many therapeutic properties are attributed to earthworm preparations. Antimicrobial, anti-inflammatory, antioxidant, antitumor, and wound healing properties of earth worm-based preparations were documented in previous studies (33-35). On the other hand, it was reported that earthworm extract provided protective properties against xenobiotics-induced organ injury (36).

The current study attempted to investigate the potential hepatoprotective role of the glycoprotein extract from the earthworm *Eisenia foetida* in two experimental models of liver injury.

2. Materials and methods

2.1. Chemicals

Hydroxymethyl aminomethane hydrochloride (Tris-HCl), trichloroacetic acid (TCA), ethylenediaminetetraacetic acid (EDTA), methanol, and n-butanol were purchased from Merck (Darmstadt, Germany). Thiobarbituric acid (TBA), potassium chloride (KCl), 5,5'-dithiobis-(2-nitrobenzoic acid; DTNB), and phosphoric acid were obtained from Sigma chemical company (Sigma-Aldrich, St. Louis, MO). All other chemicals for preparing buffer solutions were of the highest grade commercially available.

2.2. *E. foetida* extract preparation

Earthworms, *E. foetida* were purchased




Figure 1. Schematic representation for preparing the glycoprotein extract from the earthworm *Eisenia foetida*.

from the stock culture, Alborzparseh[®] Company (Shiraz, Iran). Earthworm extract was prepared according to the chloroform/methanol extraction method as previously described (37) (Figure 1). Briefly, worms were kept at 0.65% NaCl solution at room temperature for 2 h until their digestive systems became clean. Meanwhile, the solution was changed three times (Figure 1). Earthworms were kept out of the solution and minced with scissors. Then, three grams of earthworms was homogenized in 40 ml of chloroform/methanol (v/v) solution and kept overnight at 4 °C. Subsequently, 16 ml of distilled water was added to the homogenate and samples were vortexed (Figure 1). The mixture was centrifuged (10,000 g, 4 °C, 10 min) to obtain three visible layers. The upper, water/methanol layer was pipetted out, and the methanol content was removed using a rotary evaporator. The final opalescent fluid was freeze-dried and stored at 4 °C (37) (Figure 1).

2.3. Animals

Male Sprague-Dawley rats (200-250 g) and BALB/c mice (Male, 20-30 g) were purchased from the Comparative and Experimental Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Animals were acclimated to an environmentally controlled room (24±1 °C, 45%±5% relative humidity, and a 12 h light/ dark cycle). Animals had free access to a rodents commercial pellet diet (Behparvar[®], Tehran, Iran) and tap water ad libitum. The animal experiments were conducted by the guidelines for the care and use of

laboratory animals approved by the institutional animal care and use ethics committee of Shiraz University of Medical Sciences (6488/6489).

2.4. The animal model of acute liver injury

Acetaminophen (paracetamol; APAP) is a regularly used drug to induce hepatic damage in experimental animals (38-40). Mice are more susceptible to acetaminophen hepatotoxicity than rats (41). In the current investigation, a high dose of acetaminophen (1 g/kg, i.p) was administered to mice, and liver injury biomarkers were assessed 24 h after drug administration (42). EFX (500 and 700 mg/kg, i.p) was administered two h after acetaminophen. Control animals received normal saline (NaCl 0.9% w: v, 2.5 ml/kg, i.p).

2.5. Bile duct ligated (BDL) rats

Animals were anesthetized (10 mg/kg of xylazine and 70 mg/kg of ketamine, i.p), a mid-line incision was made and the common bile duct was localized, doubly ligated, and cut between these two ligatures (43-46). The sham operation consisted of laparotomy and bile duct identification and manipulation without ligation. Animals were equally allotted into four groups (n=6/group) including: 1) Sham-operated (vehicle-treated); 2) BDL; 3) BDL + EFX (100 mg/kg/day, i.p, started from day 1 after BDL operation); 4) BDL + EFX (200 mg/kg/day, i.p, started from day 1 after BDL operation), and 5) BDL + Silymarin (200 mg/kg/day, i.p, started from day 1 after BDL operation). Liver and blood samples were collected 14 days after BDL operation.

2.6. Liver glutathione content

The hepatic glutathione (GSH) content was determined by assessing non-protein sulphhydryl contents with the Ellman reagent (47, 48). Briefly, liver samples (200 mg) were homogenized in 8 ml of ice-cooled EDTA solution (20 mM, 4 °C). Then, 5 mL of homogenized tissue was mixed with 4 mL of distilled water and 1 mL of trichloroacetic acid (TCA; 50 % w/v, 4 °C). Samples were mixed and centrifuged (15 min, 10,000 g, 4 °C). Afterward, 2 mL of the supernatant was treated with 100 µl of the Ellman reagent (DTNB, 0.01M in pure methanol) (48-51), and

the absorbance of the developed color was measured at $\lambda=412$ nm using an EPOCH plate reader (BioTek®, Highland Park, USA).

2.7. Determination of lipid peroxidation in the liver tissue

Thiobarbituric acid reactive substances (TBARS) were measured as an index of liver lipid peroxidation in the liver tissue. Briefly, 500 mg of the liver tissue was gently minced and homogenized in 5 ml of ice-cooled (4 °C) KCl solution (1.15% w: v) (47, 52, 53). Afterward, .05 mL of the tissue homogenate was treated with 3.5 ml of a buffer containing 0.75 mL of thiobarbituric acid (0.8%, w:v), 0.75 mL of 20% phosphoric acid (pH=3.5) and 0.1 mL of sodium dodecyl sulfate (8.1%, w:v) (48-52, 54). Samples were heated in a water bath (100 °C, 45 min) (47, 52, 53). Then, 2 mL of n-butanol was added and vortexed (5 min). Samples were centrifuged (10,000 g for 5 min). The absorbance of developed color in the n-butanol (upper phase) was measured at $\lambda=532$ nm using an EPOCH plate reader (BioTek®, Highland Park, USA) (47, 52).

2.8. Blood biochemistry

Blood samples were collected from the abdominal vena cava. Samples were transferred to EDTA-coated or gel and clot activator containing tubes and centrifuged (10,000 g, 5 min, 4 °C) to prepare blood plasma and serum. A Mindray BS-200® autoanalyzer and standard commercial kits (Pars Azmoon®, Tehran, Iran) were used to measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (55, 56).

2.9. Histopathological studies

Liver samples were fixed in 10% phosphate-buffered formalin (0.4% sodium phosphate monobasic, NaH_2PO_4 , 0.64% sodium phosphate dibasic, Na_2HPO_4 , pH=7.4) for at least 24 h. Then, the paraffin-embedded sections were prepared and cut into 5 µm thick sections in a rotary microtome. Tissue sections were stained with the hematoxylin-eosin dye (H&E) and evaluated for histopathological alterations blindly (57).




Figure 2. Plasma biomarkers of liver injury in acetaminophen (APAP)-treated animals. EFX: *Eisenia foetida* extract; NAC: N-acetylcysteine. Data are expressed as Mean±SD (n=6).

^aIndicates significantly higher than control (Sham-operated) group ($P<0.001$).

***Indicates a significant difference as compared to the APAP group ($P<0.001$).

ns: not significant.

2.10. Statistical analysis

Data are given as Mean±SD. Comparison of data sets was performed by the one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons as the post hoc test. Values of $P<0.05$ were considered statistically significant.

3. Results

Serum biomarkers of liver injury were drastically elevated in APAP-treated mice in comparison to control animals (Figure 2). Significant

elevation in plasma ALT, AST, and total bilirubin were detected in the APAP group (Figure 2). On the other hand, it was found that EFX supplementation (500 and 700 mg/kg, i.p) decreased plasma level of liver injury biomarkers in APAP-treated animals (Figure 2). NAC administration as a standard treatment of APAP hepatotoxicity also significantly alleviated the increase in plasma biomarkers of hepatotoxicity (Figure 2).

It was found that liver tissue markers of oxidative stress were deteriorated in the APAP




Figure 3. Markers of oxidative stress in the liver tissue of acetaminophen (APAP)-treated mice and the role of *E. foetida* extract (EFX) supplementation. NAC: N-acetylcysteine.

Data are expressed as Mean±SD (n=6).

^aIndicates significantly higher than control (Sham-operated) group ($P<0.001$).

***Indicates a significant difference as compared to APAP group ($P<0.001$).

ns: no statistically significant difference.




Figure 4. Serum biomarkers of liver injury in bile duct ligated (BDL) rats. EFX: *E. foetida* extract; SLM: Silymarin. Data are expressed as Mean±SD (n=6).

^aIndicates significantly higher than the control group ($P<0.001$).

^{***}Indicates a significant difference as compared to BDL group ($P<0.001$).

ns: not significant as compared to the BDL group.

group (Figure 3). A significant increase in lipid peroxidation along with hepatic tissue glutathione depletion was evident in APAP-treated mice (Figure 3). It was found that EFX administration (500 and 700 mg/kg, i.p) mitigated APAP-induced oxidative stress in the liver tissue (Figure 3). NAC (300 mg/kg, i.p) was also able to abrogate APAP-associated oxidative stress in mice liver tissue (Figure 3).

Serum biomarkers of liver injury were significantly increased in BDL rats in comparison to control animals (Figure 4). On the other hand,

it was found that EFX supplementation (100 and 200 mg/kg, i.p for 14 consecutive days) decreased serum level of liver injury biomarkers in BDL rats (Figure 4). Administration of silymarin (200 mg/kg) also provided hepatoprotective properties in BDL animals (Figure 4).

Liver tissue markers of oxidative stress were significantly changed in BDL animals compared with the control group (Figure 5). A significant level of lipid peroxidation along with depletion of hepatic glutathione stores was evident in BDL animals (Figure 5). It was found that EFX




Figure 5. Effect of *E. foetida* extract (EFX) on liver oxidative stress markers in bile duct ligated (BDL) rats. SLM: Silymarin.

Data are expressed as Mean±SD (n=6).

^aIndicates significantly higher than control (Sham-operated) group ($P<0.001$).

^{***}Indicates a significant difference as compared to BDL group ($P<0.001$).

ns: not significant as compared to the BDL group.




Figure 6. Liver histopathological changes in acetaminophen (APAP)-treated mice and bile duct ligated (BDL) rats. The grades of liver tissue histopathological alterations are shown in Table 1. EFX: *E. foetidae* extract; SLM: Silymarin; NAC: N-acetyl cysteine.

administration (100 and 200 mg/kg, i.p for 14 consecutive days) alleviated BDL-associated oxidative stress in the liver tissue (Figure 5). Silymarin treatment (200 mg/kg, i.p for 14 consecutive days) also mitigated biomarkers of oxidative stress in the liver of BDL animals (Figure 5).

Significant liver tissue histopathological

alterations, including vascular congestion, inflammatory cells infiltration, and tissue necrosis, were evident in APAP-treated mice in comparison to control animals (Figure 6 and Table 1). On the other hand, it was found that EFX (500 and 700 mg/kg, i.p) or NAC (300 mg/kg, i.p) alleviated APAP-induced liver tissue histopathological alterations (Figure 6 and Table 1). Liver tissue necrosis, in-

Table 1. Hepatic tissue histopathological changes in the acute and chronic experimental models of liver injury.

Treatments	Congestion	Necrosis	Inflammation
Control	-	-	-
APAP	++	+++	+++
+ EFX 500 mg/kg	++	++	++
+ EFX 700 mg/kg	++	+	++
+ NAC 300 mg/kg	+	+	+
BDL	+++	+++	+++
+ EFX 100 mg/kg	++	++	++
+ EFX 100 mg/kg	++	++	++
+ SLM 200 mg/kg	++	+	+

+:Mild;

++: Moderate;

+++ :Severe tissue histopathological alterations.

EFX: *Eisenia foetida* extract;

NAC: N-acetylcysteine;

SLM: Silymarin.




Figure 7. A diagrammatic view of the potential bioactive components of earthworm extract from *Eisenia foetida* and their role in alleviating xenobiotics-induced tissue injury and the stimulation of tissue regeneration.

flammation, and vascular congestion were also evident in BDL rats (Figure 6 and Table 1). EFX supplementation (100 and 200 mg/kg, i.p for 14 consecutive days) or SLM (200 mg/kg) decreased BDL-associated liver histopathological alterations (Figure 6 and Table 1).

4. Discussion

Liver injury occasionally occurs upon exposure to different xenobiotics. The current study was designed to evaluate the hepatoprotective properties of the glycoprotein extract from *E. foetidae*. It was found that the extract supplementation alleviated blood biomarkers of liver injury and mitigated liver tissue oxidative stress in both acute and chronic animal models of hepatotoxicity.

A focus has been emerged to find new and safe molecules with therapeutic capability against different diseases. Due to its strategic role in the detoxification of xenobiotics, liver tissue is continuously exposed to a high level of foreign compounds or their reactive metabolites. Hence, finding molecules to protect the liver, boosting its regeneration capability, and enhancing its defense mechanisms has a great value.

Earthworms are widely consumed in different regions of the world as a food source or in folk medicine (58, 59). *E. foetidae* is a kind of earthworm investigated for its therapeutic value. Several biologically active compounds have been

isolated from *E. foetidae* (60-63). *E. foetida* extract has been studied for its protective properties against different xenobiotics-induced organ injury (31, 64). Several pharmacological activities including antioxidant, anti-inflammatory, and mitogenic actions have been attributed to the earthworm extract preparations (28-32). In the current study, we evaluated the potential hepatoprotective properties of the glycoprotein extract obtained from *E. foetidae* in two experimental models of acute and chronic hepatotoxicity.

Many different bioactive compounds such as glycoproteins, polysaccharides, peptides, amino acids, glutathione, and fibrinolytic enzymes have been extracted from earthworm (28-32). Although more studies are needed to precisely reveal the active component(s) of *E. foetidae* responsible for its cytoprotective effects, several mechanisms might be involved in its hepatoprotective properties (Figure 7).

The antioxidant capacity of the earthworms preparations has been documented in previous studies (30). It was proposed that the antioxidant capacity of the earthworm extract might be attributed to the presence of compounds such as polyphenol chemicals, glutathione, and amino acids (30) (Figure 7). Phenolic compounds are extracted from different earthworm species (30). Polyphenols are well-known examples of antioxidant agents, which act as free radical scavenging

molecules and counteract oxidative stress in biological environments (65). As mentioned, a high level of glutathione has been also detected in the coelomic fluids extracted from different worm types (30). In the current study, we found that *E. foetidae* extract supplementation mitigated liver tissue markers of oxidative stress in both acute and chronic animal models of hepatotoxicity. Hence, a significant part of the protective properties of this extract might be mediated through its antioxidant capacity (32, 66, 67).

The presence of growth factors and mitogenic compounds is another exciting feature associated with earthworms extracts (29, 68, 69). These compounds might be able to stimulate cell growth and tissue regeneration process (Figure 7). Therefore, a part of the hepatoprotection provided by *E. foetidae* extract, especially in a chronic animal model of liver injury, could be associated with the potential role of growth factors to stimulate liver regeneration (Figure 7). The effects of *E. foetidae* in regenerative medicine could be an interesting research area.

The anti-inflammatory properties of *E. foetidae* extract were also mentioned in previous experimental models (70). Inflammatory cells infiltration and the release of cytotoxic cytokines are also involved in the pathogenesis of liver injury in different experimental models (71). Hence, the anti-inflammatory properties of earthworm ex-

tract might contribute to its protective properties in acute and chronic models of liver injury.

Collectively, our data indicate that the glycoprotein extract from *E. foetidae* provided hepatoprotective properties in two experimental models of liver injury. Although more studies are needed to precisely reveal the molecular mechanisms involved in the hepatoprotective properties of this preparation, the antioxidant capacity of the extract seems to play a fundamental role in its mechanism of hepatoprotection. On the other hand, several other effects have been documented for the earthworm preparations in the literature. Hence, earthworms might be used as a cheap and convenient source of biologically active chemicals with broad pharmacological activities (Figure 7).

Acknowledgments

The current investigation was financially supported by the grants of the Vice Chancellor of Research Affairs of Shiraz University of Medical Sciences, Shiraz, Iran (Grant #6488/6489). The authors thank Pharmaceutical Sciences Research Center of Shiraz University of Medical Sciences for technical assistance in carrying out the current study.

Conflict of Interest

None declared.

5. References

1. Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An Overview on the Proposed Mechanisms of Antithyroid Drugs-Induced Liver Injury. *Adv Pharm Bull.* 2015;5:1-11.
2. Heidari R, Niknahad H, Jamshidzadeh A, Abdoli N. Factors affecting drug-induced liver injury: antithyroid drugs as instances. *Clin Mol Hepatol.* 2014;20:237-48.
3. Abboud G, Kaplowitz N. Drug-induced liver injury. *Drug Saf.* 2007;30:277-94.
4. Farshad O, Heidari R, Mohammadi H, Akbarizadeh AR, Zarshenas MM. Hepatoprotective effects of *Avicennia marina* (forssk.) vierh. *Trend Pharm Sci.* 2017;3:255-66.
5. Mobasher MA, Jamshidzadeh A, Heidari R, Ghahiri G, Mobasher N. Hepatoprotective ef-

- fects of *Artemia salina* L. extract against carbon tetrachloride-induced toxicity. *Trend Pharm Sci.* 2016;2:259-64.
6. Niknahad H, Heidari R, Mokhtebaz T, Mansouri S, Dehshahri S, Abdoli N, Najibi A. Evaluating the effects of different fractions obtained from *Gundelia tournefortii* extract against carbon tetrachloride-induced liver injury in rats. *Trend Pharm Sci.* 2016;2:25-34.
7. Jamshidzadeh A, Heidari R, Razmjou M, Karimi F, Moein MR, Farshad O, et al. An in vivo and in vitro investigation on hepatoprotective effects of *Pimpinella anisum* seed essential oil and extracts against carbon tetrachloride-induced toxicity. *Iran J Basic Med Sci.* 2015;18:205-11.
8. Heidari R, Babaei H, Eghbal MA. Cytoprotective effects of organosulfur compounds

against methimazole-induced toxicity in isolated rat hepatocytes. *Adv Pharm Bull.* 2013;3:135-42.

9. Zhang A, Sun H, Wang X. Recent advances in natural products from plants for treatment of liver diseases. *Eur J Med Chem.* 2013;63:570-77.
10. Schuppan D, Jia J-D, Brinkhaus B, Hahn EG. Herbal products for liver diseases: A therapeutic challenge for the new millennium. *Hepatology.* 1999;30:1099-104.
11. Niknahad H, Jamshidzadeh A, Heidari R, Zarei M, Ommati MM. Ammonia-induced mitochondrial dysfunction and energy metabolism disturbances in isolated brain and liver mitochondria, and the effect of taurine administration: relevance to hepatic encephalopathy treatment. *Clin Exp Hepatol.* 2017;3:141-51.
12. Heidari R, Jamshidzadeh A, Niknahad H, Safari F, Azizi H, Abdoli N, et al. The hepatoprotection provided by taurine and glycine against antineoplastic drugs induced liver injury in an ex vivo model of normothermic recirculating isolated perfused rat liver. *Trend Pharm Sci.* 2016;2:59-76.
13. Heidari R, Ghanbarinejad V, Mohammadi H, Ahmadi A, Ommati MM, Abdoli N, et al. Mitochondria protection as a mechanism underlying the hepatoprotective effects of glycine in cholestatic mice. *Biomed Pharmacother.* 2018;97:1086-95.
14. Jamshidzadeh A, Abdoli N, Niknahad H, Azarpira N, Mardani E, Mousavi S, et al. Taurine alleviates brain tissue markers of oxidative stress in a rat model of hepatic encephalopathy. *Trend Pharm Sci.* 2017;3:181-92.
15. Jamshidzadeh A, Heidari R, Abasvali M, Zarei M, Ommati MM, Abdoli N, et al. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia. *Biomed Pharmacother.* 2017;86:514-20.
16. Jamshidzadeh A, Heidari R, Abazari F, Ramezani M, Khodaei F, Ommati MM, et al. Antimalarial drugs-induced hepatic injury in rats and the protective role of carnosine. *Pharm Sci.* 2016;22:170-80.
17. Heidari R, Niknahad H, Jamshidzadeh A, Azarpira N, Bazyari M, Najibi A. Carbonyl traps as potential protective agents against methimazole-induced liver injury. *J Biochem Mol Toxicol.* 2015;29:173-81.
18. Jamshidzadeh A, Heidari R, Latifpour Z, Ommati MM, Abdoli N, Mousavi S, et al. Carnosine ameliorates liver fibrosis and hyperammonemia in cirrhotic rats. *Clinic Res Hepatol Gastroenterol.* 2017;41:424-34.
19. Jamshidzadeh A, Abdoli N, Niknahad H, Azarpira N, Mousavi S, Mardani E, et al. Carnosine supplementation mitigates brain tissue markers of oxidative stress in a rat model of fulminant hepatic failure. *Trend Pharm Sci.* 2017;3:149-60.
20. Heidari R, Abdoli N, Ommati MM, Jamshidzadeh A, Niknahad H. Mitochondrial impairment induced by chenodeoxycholic acid: The protective effect of taurine and carnosine supplementation. *Trend Pharm Sci.* 2018;4:99-108.
21. Adzet T, Camarasa J, Laguna JC. Hepatoprotective activity of polyphenolic compounds from *Cynara scolymus* against CCl₄ toxicity in isolated rat hepatocytes. *J Nat Prod.* 1987;50:612-7.
22. Heidari R, Ghanbarinejad V, Mohammadi H, Ahmadi A, Esfandiari A, Azarpira N, et al. Dithiothreitol supplementation mitigates hepatic and renal injury in bile duct ligated mice: Potential application in the treatment of cholestasis-associated complications. *Biomed Pharmacother.* 2018;99:1022-32.
23. Lee S-P, Yang S-C, Cheng Y-S, Lien W-J, Ng L-T. Hepatoprotection by palm tocotrienol-rich fraction. *Eur J Lipid Sci Technol.* 2010;112:712-9.
24. Tong J, Yao X, Zeng H, Zhou G, Chen Y, Ma B, et al. Hepatoprotective activity of flavonoids from *Cichorium glandulosum* seeds in vitro and in vivo carbon tetrachloride-induced hepatotoxicity. *J Ethnopharmacol.* 2015;174:355-63.
25. Ravikumar S, Gnanadesigan M. Hepatoprotective and antioxidant activity of a mangrove plant *Lumnitzera racemosa*. *Asian Pacific J Trop Biomed.* 2011;1:348-32.
26. Sabine JR. Earthworms as a source of food and drugs. *Earthworm ecology*: Springer; 1983. p. 285-296.
27. Cooper EL, Balamurugan M, Huang C-Y, Tsao CR, Heredia J, Tommaso-Ponzetta M, et al. Earthworms dilong: Ancient, inexpensive, non-controversial models may help clarify approaches to integrated medicine emphasizing neuroimmune systems. *Evid Based Complement Alternat Med.* 2012:2012.
28. Hanušová R, Bilej M, Brys L, De-Baetselier P, Beschin A. Identification of a coelomic

mitogenic factor in *Eisenia foetida* earthworm. *Immunol Lett.* 1999;65:203-11.

29. Hrženjak M, Kobrehel Dj, Levanat S, Jurin M, Hrženjak T. Mitogenicity of the earthworm's (*Eisenia foetida*) insulin-like proteins. *Comp Biochem Physiol Part B: Comp Biochem.* 1993;104:723-9.

30. Aldarraji QM, Halimoon N, Majid NM. Antioxidant activity and total phenolic content of earthworm paste of *Lumbricus rubellus* (red worm) and *Eudrilus eugenia* (African night crawler). *J Entomol Nematol.* 2013;5:33-7.

31. Prakash M, Gunasekaran G, Elumalai K. Effect of earthworm powder on antioxidant enzymes in alcohol induced hepatotoxic rats. *Eur Rev Med Pharmacol Sci.* 2008;12:237-43.

32. Grdisa M, Popovic M, Hrzenjak T. Glycolipoprotein extract (G-90) from earthworm *Eisenia foetida* exerts some antioxidative activity. *Comp Biochem Physiol A Mol Integr Physiol.* 2001;128:821-5.

33. Zhao H, Dong J, Lu J, Chen J, Li Y, Shan L, et al Effects of extraction solvent mixtures on antioxidant activity evaluation and their extraction capacity and selectivity for free phenolic compounds in barley (*Hordeum vulgare* L.). *J Agric Food Chem.* 2006;54:7277-86.

34. Li W, Wang C, Sun Z. Vermipharmaceuticals and active proteins isolated from earthworms. *Pedobiologia.* 2011;54:S49-S56.

35. Liu Y-Q, Sun Z-J, Wang C, Li S-J, Liu Y-Z. Purification of a novel antibacterial short peptide in earthworm *Eisenia foetida*. *Acta Biochimica Biophysica.* 2004;36:297-302.

36. Jamshidzadeh A, Heidari R, Golzar T, Derakhshanfar A. Effect of *Eisenia foetida* Extract against Cisplatin-Induced Kidney Injury in Rats. *J Diet Suppl.* 2016;13:551-9.

37. Balamurugan M, Parthasarathi K, Cooper EL, Ranganathan LS. Anti-inflammatory and anti-pyretic activities of earthworm extract-*Lampito mauritii* (Kinberg). *J Ethnopharmacol.* 2009;121:330-2.

38. Nafisi S, Heidari R, Ghaffarzadeh M, Ziaee M, Hamzeiy H, Garjani A, et al. Cytoprotective effects of silafibrate, a newly-synthesised siliconated derivative of clofibrate, against acetaminophen-induced toxicity in isolated rat hepatocytes. *Arh Hig Rada Toksikol.* 2014;65:169-78.

39. Heidari R, Jamshidzadeh A, Niknahad H,

Mardani E, Ommati MM, Azarpira N, et al. Effect of taurine on chronic and acute liver injury: Focus on blood and brain ammonia. *Toxicol Rep.* 2016;3:870-9.

40. Ommati MM, Jamshidzadeh A, Niknahad H, Mohammadi H, Sabouri S, Heidari R, et al. N-acetylcysteine treatment blunts liver failure-associated impairment of locomotor activity. *PharmaNutrition.* 2017;5:141-7.

41. McGill MR, Williams CD, Xie Y, Ramachandran A, Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. *Toxicol Appl Pharmacol.* 2012;264:387-94.

42. Liu LC, Wang CJ, Lee CC, Su SC, Chen HL, Hsu JD, et al. Aqueous extract of *Hibiscus sabdariffa* L. decelerates acetaminophen-induced acute liver damage by reducing cell death and oxidative stress in mouse experimental models. *J Sci Food Agricult.* 2010;90:329-37.

43. Moezi L, Heidari R, Amirghofran Z, Nekooeian AA, Monabati A, Dehpour AR. Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: The role of nitric oxide and IL-1b. *Pharmacol Rep.* 2013;65:134-43.

44. Heidari R, Jamshidzadeh A, Ghanbarinejad V, Ommati MM, Niknahad H. Taurine supplementation abates cirrhosis-associated locomotor dysfunction. *Clin Exp Hepatol.* 2018;4:72-82.

45. Heidari R, Niknahad H, Sadeghi A, Mohammadi H, Ghanbarinejad V, Ommati MM, et al. Betaine treatment protects liver through regulating mitochondrial function and counteracting oxidative stress in acute and chronic animal models of hepatic injury. *Biomed Pharmacother.* 2018;103:75-86.

46. Heidari R, Moezi L, Asadi B, Ommati MM, Azarpira N. Hepatoprotective effect of boldine in a bile duct ligated rat model of cholestasis/cirrhosis. *PharmaNutrition.* 2017;5:109-17.

47. Ahmadian E, Eftekhari A, Khalili Fard J, Babaei H, Mohajjel Nayeibi A, Mohammadnejad D, et al. In vitro and in vivo evaluation of the mechanisms of citalopram-induced hepatotoxicity. *Arch Pharm Res.* 2017;40:1296-313.

48. Heidari R, Babaei H, Roshangar L, Eghbal MA. Effects of Enzyme Induction and/or Glutathione Depletion on Methimazole-Induced Hepatotoxicity in Mice and the Protective Role of

- N-Acetylcysteine. *Adv Pharm Bull.* 2014;4:21-8.
49. Heidari R, Babaei H, Eghbal MA. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. *Res Pharm Sci.* 2014;9:97-105.
50. Jamshidzadeh A, Heidari R, Abazari F, Ramezani M, Khodaei F, Ommati MM, et al. Antimalarial drugs-induced hepatic injury in rats and the protective role of carnosine. *Pharm Sci.* 2016;22:170-80.
51. Niknahad H, Heidari R, Firuzi R, Abazari F, Ramezani M, Azarpira N, et al. Concurrent inflammation augments antimalarial drugs-induced liver injury in rats. *Adv Pharm Bull.* 2016;6:617-25.
52. Heidari R, Jamshidzadeh A, Keshavarz N, Azarpira N. Mitigation of methimazole-induced hepatic injury by taurine in mice. *Sci Pharm.* 2015;83:143-58.
53. Ommati MM, Tanideh N, Rezakhaniha B, Wang J, Sabouri S, Vahedi M, et al. Is immunosuppression, induced by neonatal thymectomy, compatible with poor reproductive performance in adult male rats? *Andrology.* 2018;6:199-213.
54. Heidari R, Ahmadi A, Mohammadi H, Ommati MM, Azarpira N, Niknahad H. Mitochondrial dysfunction and oxidative stress are involved in the mechanism of methotrexate-induced renal injury and electrolytes imbalance. *Biomed Pharmacother.* 2018;107:834-40.
55. Heidari R, Babaei H, Eghbal MA. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. *Res Pharm Sci.* 2014;9:97-105.
56. Heidari R, Ahmadi F, Rahimi HR, Azarpira N, Hosseinzadeh M, Najibi A, et al. Exacerbated liver injury of antithyroid drugs in endotoxin-treated mice. *Drug Chem Toxicol.* 2018;1-9.
57. Eftekhari A, Ahmadian E, Azarmi Y, Parvizpur A, Hamishehkar H, Eghbal MA. In vitro/ vivo studies towards mechanisms of risperidone-induced oxidative stress and the protective role of coenzyme Q10 and N-acetylcysteine. *Toxicol Mechanism Method.* 2016;26:520-8.
58. Costa-Neto EM. Animal-based medicines: biological prospection and the sustainable use of zootherapeutic resources. *An Acad Bras Cienc.* 2005;77:33-43.
59. Cooper EL, Ru B, Weng N. Earthworms: Sources of antimicrobial and anticancer molecules. *Complementary and Alternative Approaches to Biomedicine. Advances in Experimental Medicine and Biology: Springer, Boston, MA;*2004. p.359-389.
60. Grdisa M, Popovic M, Hrzenjak T. Glycolipoprotein extract (G-90) from earthworm *Eisenia foetida* exerts some antioxidative activity. *Comp Biochem Physiol A Mol Integr Physiol.* 2001;128:821-5.
61. Hrzenjak T, Popović M, Božić T, Grdisa M, Kobrehel D, Tiska-Rudman L. Fibrinolytic and anticoagulative activities from the earthworm *Eisenia foetida*. *Comp Biochem Physiol B Biochem Mol Biol.* 1998;119:825-32.
62. Xie J, He W, Weng N, Guo Z, Yu M, Liu N, et al. Extraction and isolation of the anti-tumor protein components from earthworm (*Eisenia foetida* Andrei) and the anti-tumor activity. *Chin J Biochem Mol Biol.* 2002;19:359-66.
63. Yang J-S, Ru B-G. Purification and Characterization of an SDS-Activated Fibrinolytic Enzyme from *Eisenia foetida*. *Comp Biochem Physiol B Biochem Mol Biol.* 1997;118:623-31.
64. Balamurugan M. Restoration of histoarchitecture in the paracetamol-induced liver damaged rat by earthworm extract, *Lampito mauritii* (Kinberg). *Eur Rev Med Pharmacol Sci.* 2007;11:407-11.
65. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. *Am J Clin Nutr.* 2005;81:215S-217S.
66. Matausijć-Pisl M, Cupić H, Kasuba V, Mikecin AM, Grdisa M. Tissue extract from *Eisenia foetida* as a wound-healing agent. *Eur Rev Med Pharmacol Sci.* 2010;14:177-84.
67. Grdisa M, Popović M, Hrzenjak T. Stimulation of growth factor synthesis in skin wounds using tissue extract (G-90) from the earthworm *Eisenia foetida*. *Cell Biochem Funct.* 2004;22:373-8.
68. Mira G, Terezija H. Glycolipoprotein extract of *Eisenia foetida* (G-90): A source of biological active molecules. *Eur J Soil Biol.* 2007;43:S104-S109.
69. Balamurugan M, Parthasarathi K, Cooper EL, Ranganathan LS. Anti-inflammatory and anti-pyretic activities of earthworm extract—*Lampito mauritii* (Kinberg). *J Ethnopharmacol.* 2009;121:330-2.
70. Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI. Role of Proinflammatory

Akram Jamshidzadeh *et al.*

Cytokines in Acetaminophen Hepatotoxicity. *Toxicol Appl Pharmacol.* 1995;133:43-52.

71. Seki E, Schwabe RF. Hepatic inflamma-

tion and fibrosis: Functional links and key pathways. *Hepatology.* 2015;61:1066-79.